companiesCompany

AVEO Oncology (LG Chem)

AVEO Oncology developed tivozanib and was acquired by LG Chem in 2023.

Fotivda (tivozanib) in relapsed RCC; TiNivo-2 negative for IO rechallenge; ficlatuzumab (HGF) in head and neck cancer.

Headquarters

Boston, MA, US

Type

biotech

Website

www.aveooncology.com

Products

1top

ApprovedSmall-molecule kinase inhibitor (VEGFR)

Tivozanib · Fotivda

Tivozanib is a highly selective VEGF-receptor pill for kidney cancer after two or more prior treatments, notable for its tolerability and for a trial that closed the door on immunotherapy rechallenge.

Connected

3top

Pages like this

not linked directly; found by shared links

Trial
TiNivo-2
Shares Tivozanib, Renal cell carcinoma.
Pairing
Caution: PD-1 rechallenge after progression on immunotherapy (RCC)
Shares Tivozanib, Renal cell carcinoma.
Pathway
The angiogenic switch & tumour vessels
Shares Tivozanib, Renal cell carcinoma.

AVEO Oncology (LG Chem)

Products

Connected

Pages like this

cancers

fronts

drugs